Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults

Digestive Diseases and Sciences

Volumn 51, Issue 1, 2006, Pages 123-131

  Pratha, Vijaya S ^a,c   Hogan, Daniel L ^a   Lane, James R ^a   Williams, Paul J ^a   Burton, Michael S ^b   Lynn, Richard B ^b   Karlstadt, Robyn G ^b  

^a Clinical Applications Laboratories   (United States)

^b PFIZER INC   (United States)

^c CAL Inc   (United States)

Author keywords

Gastric acid output; Maximal acid output; Omeprazole; Pantoprazole; Proton pump inhibitors

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; ION TRANSPORT; MALE; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PENTAGASTRIN; PROSPECTIVE STUDIES; REFERENCE VALUES; STOMACH; SULFOXIDES;

EID: 30844441665     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-3096-0     Document Type: Article

References (22)

1. Medical Economics Company, Inc.: Prescribing information: Protonix® delayed-release tablets. In Physicians' Desk Reference. Montvale, NJ, Medical Economics Company, Inc., 2002, pp 3577-3580
2. Medical Economics Company, Inc.: Prescribing information: Prilosec®. In Physicians' Desk Reference. Montvale, NJ, Medical Economics Company, Inc. 2002, pp 628-632
3. Andersson T, Röhss K, Bredberg E, Hassan-Alin M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 15:1563-1569, 2001
4. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K: Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861-867, 2000
5. Röhss K, Hasselgren G, Hedenström H: Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 47:954-958, 2002
6. Feldman M: Gastric secretion: normal and abnormal. In Sleisenger & Fordtran's Gastrointestinal and Liver Diseases. Feldman M, Scharschmidt BF, Sleisenger MH (eds). Philadelphia, W. B. Saunders, 1998, pp 587-603
7. Mason MC, Giles GR, Clark CG: Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion. Gut 10:34-38, 1969
8. Pisegna JR, Martin P, McKeand W, Ohning G, Walsh JH, Paul J: Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. Am J Gastroenterol 94:2877-2880, 1999
9. Soll AH: Peptic ulcer and its complications. In Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Feldman M, Scharschmidt BF, Sleisenger MH (eds). Philadelphia, PA, W. B. Saunders, 1998, pp 620-678
10. Hassan MA, Hobsley M: Positioning of subject and of nasogastric tube during a gastric secretion study. Br Med J 1:458-460, 1970
11. Findlay JM, Prescott RJ, Sircus W: Comparative evaluation of water recovery test and fluoroscopic screening in positioning a nasogastric tube during gastric secretory studies. Br Med J 4:458-461, 1972
12. Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, Pisegna JR: Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 96:3274-3280, 2001
13. Brunner G, Hell M, Hengels KJ, Hennig U, Fuchs W: Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion 56:137-144, 1995
14. Nishina K, Mikawa K, Takao Y, Shiga M, Maekawa N, Obara H: A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg 90:717-721, 2000
15. Ehrlich A, Lücker PW, Wiedemann A, Sander P, Huber R, Mascher H: Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 21:47-51, 1999
16. Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 10:359-366, 1996
17. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T: Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 23:19-26, 1998
18. Sachs G: Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17:22-37, 1997
19. Kittang E, Aadland E, Schjonsby H: Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut 26:594-598, 1985
20. Rubinstein E, Hojgaard L: The effect of intravenous omeprazole on the gastric and duodenal potential difference and pH in healthy subjects. Digestion 54:15-18, 1993
21. Richter JE, Bochenek W: Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 95:3071-3080, 2000
22. Metz DC, Bochenek WJ: Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 17:155-164, 2003